13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001599882
Total reported value
$1.1B
$1.1B
92 檔
15.7%
The Q3 2025 SEC filing reveals that Rhenman & Partners Asset Management AB held a total portfolio value of $1.1B, covering 92 public equity positions.
Rhenman & Partners Asset Management AB executed strategic sector rebalancing during Q3 2025, establishing 21 new positions while fully exiting 23 holdings and trimming 26 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BSX | Boston Scientific CORP | Stock-Healthcare | 4.73% | -3.03% | +47.97% | |
| 2 | LLY | Eli Lilly & Co | Stock-Healthcare | 4.51% | -1.30% | -7.69% | |
| 3 | ABBV | Abbvie Inc | Stock-Healthcare | 3.34% | +0.38% | +87.93% | |
| 4 | DHR | Danaher CORP | Stock-Healthcare | 2.95% | +1.02% | +10.70% | |
| 5 | ALHC | Alignment Healthcare Inc | Stock-Other | 2.86% | -0.05% | +14.92% | |
| 6 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 2.40% | -0.80% | +9.36% | |
| 7 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 2.39% | +2.15% | +105.49% | |
| 8 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 2.32% | +0.13% | +90.31% | |
| 9 | CVS | Cvs Health CORP | Stock-Healthcare | 2.31% | -0.25% | -6.09% | |
| 10 | MCK | Mckesson CORP | Stock-Healthcare | 2.27% | -0.62% | -4.03% | |
| 11 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 2.25% | -2.98% | +30.32% | |
| 12 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 2.24% | -0.41% | +70.33% | |
| 13 | MDT | Medtronic plc | Stock-Healthcare | 2.16% | +0.11% | +14.21% | |
| 14 | COR | Cencora Inc | Stock-Healthcare | 2.16% | -0.78% | +26.33% | |
| 15 | EXK | Exact Sciences CORP | Stock-Materials | 2.11% | — | -0.57% | |
| 16 | INSM | Insmed Inc | Stock-Healthcare | 2.10% | -1.69% | -24.82% | |
| 17 | GKOS | Glaukos CORP | Stock-Healthcare | 2.08% | +0.45% | -2.13% | |
| 18 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 2.03% | -0.96% | -23.59% | |
| 19 | PODD | Insulet CORP | Stock-Healthcare | 1.98% | +0.24% | +26.09% | |
| 20 | COO | Cooper Cos Inc/the | Stock-Healthcare | 1.80% | -0.07% | +39.41% | |
| 21 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 1.78% | -0.27% | -23.12% | |
| 22 | EHC | Encompass Health CORP | Stock-Healthcare | 1.68% | +0.04% | -12.46% | |
| 23 | CAH | Cardinal Health Inc | Stock-Healthcare | 1.63% | -0.20% | +70.91% | |
| 24 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 1.61% | -1.02% | +169.66% | |
| 25 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 1.61% | -0.92% | -37.74% | |
| 26 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.55% | — | +144.84% | |
| 27 | PRCT | Procept Biorobotics CORP | Stock-Other | 1.54% | -0.73% | +105.26% | |
| 28 | CI | THE Cigna Group | Stock-Healthcare | 1.48% | +0.19% | +45.31% | |
| 29 | ABT | Abbott Laboratories | Stock-Healthcare | 1.46% | -0.60% | +68.38% | |
| 30 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 1.39% | +0.22% | -12.84% | |
| 31 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.33% | +0.61% | +181.82% | |
| 32 | THC | Tenet Healthcare CORP | Stock-Healthcare | 1.31% | +0.24% | -57.17% | |
| 33 | AKRO | Akero Therapeutics Inc | Stock-Other | 1.21% | — | +16.70% | |
| 34 | ALGN | Align Technology Inc | Stock-Healthcare | 1.15% | +0.84% | +24.81% | |
| 35 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 1.12% | +0.13% | +24.72% | |
| 36 | DOCS | Doximity Inc-class A | Stock-Healthcare | 1.10% | -0.38% | +547.62% | |
| 37 | RPRX | Royalty Pharma plc | Stock-Healthcare | 1.01% | -0.34% | -24.85% | |
| 38 | GILD | Gilead Sciences Inc | Stock-Healthcare | 0.98% | -0.75% | -52.33% | |
| 39 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.98% | +0.07% | — | |
| 40 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 0.93% | -1.14% | — | |
| 41 | BIIB | Biogen Inc | Stock-Healthcare | 0.85% | -0.54% | +358.33% | |
| 42 | DVAX | Dynavax Technologies CORP | Stock-Other | 0.85% | — | +36.64% | |
| 43 | ADPT | Adaptive Biotechnologies | Stock-Other | 0.82% | -1.23% | EXIT | |
| 44 | ELV | Elevance Health Inc | Stock-Healthcare | 0.80% | +0.10% | -49.61% | |
| 45 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.76% | -0.06% | +37.12% | |
| 46 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.69% | +0.18% | — | |
| 47 | CNC | Centene CORP | Stock-Healthcare | 0.67% | +1.48% | NEW | |
| 48 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.65% | -0.13% | — | |
| 49 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 0.63% | -0.17% | +154.46% | |
| 50 | AVR | Anteris Technologies Global | Stock-Other | 0.62% | +0.44% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | DHR | Danaher CORP | +2% | +10.70% | Add |
| 2 | IONS | Ionis Pharmaceuticals Inc | +2% | +70.33% | Add |
| 3 | BSX | Boston Scientific CORP | +1.3% | +47.97% | Add |
| 4 | EHC | Encompass Health CORP | +1.2% | -12.46% | Add |
| 5 | ABBV | Abbvie Inc | +1.2% | +87.93% | Add |
| 6 | COR | Cencora Inc | +1.1% | +26.33% | Add |
| 7 | CYTK | Cytokinetics Inc | +1.1% | +144.84% | Add |
| 8 | TMO | Thermo Fisher Scientific Inc | +0.9% | +169.66% | Add |
| 9 | AXSM | Axsome Therapeutics Inc | +0.9% | +90.31% | Add |
| 10 | AKRO | Akero Therapeutics Inc | +0.8% | +16.70% | Add |
| 11 | ABT | Abbott Laboratories | +0.7% | +68.38% | Add |
| 12 | NBIX | Neurocrine Biosciences Inc | +0.6% | -23.12% | Add |
| 13 | LLY | Eli Lilly & Co | +0.6% | -7.69% | Add |
| 14 | APLSUSD | Apellis Pharmaceuticals Inc | +0.5% | +149.06% | Add |
| 15 | PEN | Penumbra Inc | +0.5% | -4.65% | Add |
| 16 | DNTH | Dianthus Therapeutics Inc | +0.5% | +37.12% | Add |
| 17 | CVS | Cvs Health CORP | +0.5% | -6.09% | Add |
| 18 | INSM | Insmed Inc | +0.5% | -24.82% | Trim |
| 19 | GPCR | Structure Therapeutics Inc | +0.4% | +33.31% | Add |
| 20 | CI | THE Cigna Group | +0.4% | +45.31% | Add |
| 21 | ALGN | Align Technology Inc | +0.4% | +24.81% | Add |
| 22 | SNDX | Syndax Pharmaceuticals Inc | +0.4% | — | Add |
| 23 | VKTX | Viking Therapeutics Inc | +0.4% | +154.46% | Add |
| 24 | BRKR | Bruker CORP | +0.4% | +25.14% | Add |
| 25 | KURA | Kura Oncology Inc | +0.3% | +96.00% | Add |
| 26 | PRVA | Privia Health Group Inc | +0.3% | +112.95% | Add |
| 27 | ACLXGBX | Arcellx Inc | +0.3% | -2.97% | Add |
| 28 | XENE | Xenon Pharmaceuticals Inc | +0.2% | +131.43% | Add |
| 29 | INSP | Inspire Medical Systems Inc | +0.2% | +100.00% | Add |
| 30 | ✓ | Merus N V | +0.2% | -53.88% | Trim |
| 31 | ANNX | Annexon Inc | +0.2% | +78.91% | Add |
| 32 | ALKS | Alkermes plc | +0.2% | +141.03% | Add |
| 33 | PODD | Insulet CORP | +0.1% | +26.09% | Trim |
| 34 | RLAY | Relay Therapeutics Inc | +0.1% | — | Unchanged |
| 35 | ALNY | Alnylam Pharmaceuticals Inc | +0.1% | -37.74% | Trim |
| 36 | AVR | Anteris Technologies Global | +0.1% | — | Trim |
| 37 | MIRM | Mirum Pharmaceuticals Inc | +0.1% | -14.45% | Trim |
| 38 | BIIB | Biogen Inc | +0.1% | +358.33% | Add |
| 39 | NUVL | Nuvalent Inc-a | +0.1% | — | Unchanged |
| 40 | RARE | Ultragenyx Pharmaceutical In | +0.1% | +28.25% | Add |
| 41 | BNTX | Biontech Se-adr | 0% | — | Add |
| 42 | NRIX | Nurix Therapeutics Inc | 0% | +87.84% | Add |
| 43 | DVAX | Dynavax Technologies CORP | 0% | +36.64% | Add |
| 44 | IOVA | Iovance Biotherapeutics Inc | 0% | +69.46% | Add |
| 45 | IMCR | Immunocore Holdings Plc-adr | 0% | — | Unchanged |
| 46 | ALHC | Alignment Healthcare Inc | — | +14.92% | Add |
| 47 | DNLI | Denali Therapeutics Inc | — | — | Unchanged |
| 48 | XNCR | Xencor Inc | 0% | — | Trim |
| 49 | MLTX | Moonlake Immunotherapeutics | 0% | +360.00% | Add |
| 50 | IQV | Iqvia Holdings Inc | 0% | +50.00% | Trim |
According to official SEC Form 13F filings, Rhenman & Partners Asset Management AB reported a total U.S. public equity portfolio value of $1.1B across 92 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including BSX, LLY, ABBV) accounted for 15.7% of total reported equity market value during Q3 2025.
Top New Position Initiated
CAH
市值: $14.8M
Top Position Liquidated / Trimmed
MOH
前期市值: $22.5M
During Q3 2025, Rhenman & Partners Asset Management AB's top holdings by market value included BSX (4.7%)、LLY (4.5%)、ABBV (3.3%). The largest single position, BSX, represented 4.7% of total portfolio value.
In Q3 2025, Rhenman & Partners Asset Management AB made 111 total portfolio adjustments, initiating 21 new buys, adding to 41 positions, trimming 26 holdings, and fully liquidating 23 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.